
|Videos|June 11, 2019
Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLC
Author(s)Anna F. Farago, MD, PhD
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.
Advertisement
Cancer Network spoke with Anna F. Farago, MD, medical oncologist at Massachusetts General Hospital, about the effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan. The results (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer
2
FDA Accepts BLA for Ivonescimab Regimen in Pretreated EGFR-Mutated NSCLC
3
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
4
FDA Clears IND for Investigational Program in Recurrent High-Grade Glioma
5


































